Start / PharmaTalkRadio / Investment trends in immuno oncology

PharmaTalkRadio

Investment Trends in Immuno-Oncology

39 min • 22 januari 2025

Summary:
In this podcast, recorded at the February 2024 IO360º summit, biopharma, finance and investment experts discuss the fundability features of IO biotechs, and the current pharma needs that will drive potential partnerships or M&A.

Moderater:
Axel Hoos, MD, PhD, Former CEO, Scorpion Therapeutics

Panelists:
Irina Margine, PhD, Principal, Biotech Private Equity, Wellington Management
Khalil Barrage, Managing Partner, Invus Group
Jeffrey Bockman, PhD, EVP, Oncology and Virology Practices, Lumanity
Emmett Schmidt, MD, PhD, VP, Clinical Oncology, External Collaborations, Merck
Gayatri Varma, PhD, Executive Director and Head of Transactions, Oncology R&D, AstraZeneca

For more information, go to IO360summit.com.

Senaste avsnitt

Directors' Talk DPHARM 2025 - AI Sessions; Part III

25 juli | 6 min

Innovations in Manufacturing to Make CAR-T More Accessible and Affordable

25 juli | 20 min

Achieving Oral Delivery of Peptides through Formulation and Molecule Design Approaches

25 juli | 29 min

Catalyzing Change: The Business Imperative of Patient-Centric Drug Development

21 juli | 26 min

How Emerging Biopharma CMOs Can Better Partner with Patient Organizations

21 juli | 32 min

Podcastbild

00:00 -00:00

Podcastbild

00:00 -00:00